Portolan Capital Management LLC Has $6.36 Million Stock Position in Establishment Labs Holdings Inc. $ESTA

Portolan Capital Management LLC raised its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 24.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,096 shares of the company’s stock after purchasing an additional 30,704 shares during the quarter. Portolan Capital Management LLC owned approximately 0.53% of Establishment Labs worth $6,357,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP raised its stake in shares of Establishment Labs by 2,089.5% during the 3rd quarter. Marshall Wace LLP now owns 136,012 shares of the company’s stock worth $5,575,000 after purchasing an additional 129,800 shares in the last quarter. Mudita Advisors LLP grew its stake in shares of Establishment Labs by 14.3% in the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock valued at $28,150,000 after buying an additional 86,100 shares in the last quarter. Sei Investments Co. grew its stake in shares of Establishment Labs by 2.8% in the 3rd quarter. Sei Investments Co. now owns 49,770 shares of the company’s stock valued at $2,040,000 after buying an additional 1,342 shares in the last quarter. Tyro Capital Management LLC increased its holdings in Establishment Labs by 1.0% in the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock worth $44,165,000 after buying an additional 10,735 shares during the last quarter. Finally, Private Advisor Group LLC raised its position in Establishment Labs by 14.1% during the third quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after acquiring an additional 675 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on ESTA shares. Wall Street Zen upgraded shares of Establishment Labs from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. JPMorgan Chase & Co. increased their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Needham & Company LLC raised their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Stephens lifted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Mizuho upped their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

Establishment Labs Stock Down 0.4%

ESTA opened at $63.35 on Friday. The firm has a market cap of $1.86 billion, a P/E ratio of -36.41 and a beta of 0.91. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The business has a 50 day moving average price of $70.25 and a 200 day moving average price of $60.41. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. During the same quarter last year, the company posted ($1.19) earnings per share. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. Research analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.